Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $15.00 price target on the stock.
Invivyd Trading Down 12.8 %
Shares of IVVD traded down $0.13 during trading hours on Tuesday, reaching $0.91. 991,637 shares of the company traded hands, compared to its average volume of 637,039. The firm has a market cap of $108.21 million, a price-to-earnings ratio of -0.49 and a beta of 0.63. Invivyd has a 12-month low of $0.81 and a 12-month high of $5.20. The stock's fifty day moving average price is $0.99 and its 200 day moving average price is $1.42.
Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.03). The firm had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. On average, research analysts forecast that Invivyd will post -0.6 earnings per share for the current year.
Hedge Funds Weigh In On Invivyd
Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock valued at $11,594,000 after buying an additional 97,496 shares in the last quarter. Marshall Wace LLP boosted its stake in Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after acquiring an additional 31,992 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Duquesne Family Office LLC purchased a new position in Invivyd in the second quarter worth $629,000. Finally, Jacobs Levy Equity Management Inc. increased its position in shares of Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company's stock worth $1,933,000 after purchasing an additional 77,603 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Featured Stories
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
